Analysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) PT at $68.00

Travere Therapeutics, Inc. (NASDAQ:TVTX) has received an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $68.00.

A number of equities analysts have weighed in on TVTX shares. Guggenheim increased their target price on shares of Travere Therapeutics from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright boosted their price target on shares of Travere Therapeutics from $57.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research note on Friday, June 12th. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $62.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, TD Cowen lifted their price objective on shares of Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $62.76 on Wednesday. The company has a debt-to-equity ratio of 24.58, a current ratio of 4.05 and a quick ratio of 3.99. The stock has a market capitalization of $5.92 billion, a PE ratio of -136.43 and a beta of 1.05. Travere Therapeutics has a one year low of $22.06 and a one year high of $68.73. The business’s fifty day moving average price is $61.76 and its 200-day moving average price is $48.74.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.03. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The company had revenue of $169.58 million during the quarter, compared to analyst estimates of $157.27 million. During the same quarter last year, the firm posted $0.13 EPS. The firm’s revenue for the quarter was up 48.2% on a year-over-year basis. On average, equities research analysts anticipate that Travere Therapeutics will post -0.54 EPS for the current year.

Insider Transactions at Travere Therapeutics

In other news, CEO Eric Dube sold 195,841 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $63.45, for a total value of $12,426,111.45. Following the completion of the transaction, the chief executive officer directly owned 432,886 shares of the company’s stock, valued at $27,466,616.70. This trade represents a 31.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Cline sold 50,508 shares of Travere Therapeutics stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $3,148,668.72. Following the completion of the transaction, the chief financial officer owned 87,508 shares of the company’s stock, valued at approximately $5,455,248.72. This trade represents a 36.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,050,294 shares of company stock valued at $66,336,443. 4.44% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TVTX. Jupiter Topco LLC purchased a new position in Travere Therapeutics during the second quarter valued at approximately $643,299,000. Bank of America Corp DE purchased a new stake in Travere Therapeutics in the 2nd quarter worth approximately $259,527,000. Fiera Capital Corp purchased a new stake in Travere Therapeutics in the 4th quarter worth approximately $33,398,000. Wellington Management Group LLP boosted its holdings in Travere Therapeutics by 50.0% in the 2nd quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company’s stock valued at $87,094,000 after purchasing an additional 510,808 shares during the period. Finally, Perceptive Advisors LLC boosted its holdings in Travere Therapeutics by 12.7% in the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock valued at $163,469,000 after purchasing an additional 483,565 shares during the period.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts maintain a generally favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $68. Several firms have raised their targets to $70-$78, suggesting potential upside from recent trading levels. Travere Therapeutics analyst coverage
• Positive Sentiment: Institutional interest has increased, including new positions from Jupiter Topco and Bank of America, while Wellington Management and Perceptive Advisors expanded their holdings. The buying may reinforce confidence in Travere’s commercial prospects and rare-disease pipeline.
• Neutral Sentiment: Travere will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on FILSPARI and the company’s pipeline, although no new business information was announced. Travere presentation announcement
• Negative Sentiment: Multiple executives and insiders reported selling shares, including CEO Eric Dube, CFO Christopher Cline, CAO Sandra Calvin and several executive vice presidents. Collectively, the disclosed transactions represented roughly $61 million of stock sales, with individual holdings falling by approximately 6% to 60%. The trades were conducted under pre-arranged Rule 10b5-1 plans, which lessens their signaling value, but the concentration of selling may still weigh on investor sentiment and near-term momentum.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.